Clinical Trial Update: Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating arsenic trioxide in combination with MAPK inhibitors and chemotherapy for stage 4/metastatic neuroblastoma is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Trisenox (arsenic trioxide)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Neuroblastoma | Phase 2 | Status: RECRUITING